Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 2, 2003, Pages 402-408

  Antonadou, Dosia ^a   Throuvalas, Nikolas ^a   Petridis, Aris ^a   Bolanos, Nicolas ^a   Sagriotis, Alexandros ^a   Synodinou, Maria ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Amifostine; Cytoprotectant; Non small cell lung cancer; Radiochemotherapy; Toxicity

Indexed keywords

BLOOD; CELLS; RADIOTHERAPY; TOXICITY; TUMORS;

RADIOCHEMOTHERAPY;

ONCOLOGY;

AMIFOSTINE; CARBOPLATIN; PACLITAXEL; RADIOPROTECTIVE AGENT;

ACUTE DISEASE; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BIOSAFETY; BLOOD CELL COUNT; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; ESOPHAGITIS; FEMALE; HUMAN; INCIDENCE; INTOXICATION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 0042383184     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00590-X     Document Type: Article

References (37)

1. Landis S.H., Murray T., Bolden S. Cancer statistics, 1999. CA Cancer J Clin. 49:1999;8-31.
2. Movsas B. Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer. Cancer Control. 7:2000;25-34.
3. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer. 10:1994;S239-S244.
4. Jeremic B., Shibamoto Y., Acimovic L., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer A randomized study . J Clin Oncol. 14:1996;1065-1070.
5. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial . J Natl Cancer Inst. 88:1996;1210-1215.
6. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC) Identification of five groups with different survival . Int J Radiat Oncol Biol Phys. 48:2000;1475-1482.
7. Choi N.C., Carey R.W., Daly W., et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol. 15:1997;712-722.
8. Belani C.P. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer. Semin Oncol. 26:(1 Suppl. 2):1999;44-54.
9. Choy H., MacRae R. The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer. Semin Oncol. 28:(Suppl. 14):2001;17-22.
10. Gaspar L.E. Optimizing chemoradiation therapy approaches to unresectable stage III non-small cell lung cancer. Curr Opin Oncol. 13:2001;110-115.
11. Vokes E.E., Green M.R. Current strategies for locoregionally advanced unresectable non-small cell lung cancer. Semin Oncol. 26:(5 Suppl 15):1999;40-43.
12. Curran W.J., Scott C., Langer C., et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC) Initial report of Radiation Therapy Oncology Group (RTOG) 9410 . (Abstr.) Proc Am Soc Clin Oncol. 19:2000;1891a.
13. Komaki R., Seriferheld W., Curran W., et al. Sequential versus concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC) Analysis of failures in a phase III study (RTOG 9410) . (Abstr.) Int J Radiat Oncol Biol Phys. 48:2000;5.
14. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
15. Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomized clinical trials . BMJ. 311:1995;899-909.
16. Pignon J.P., Stewart L.A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small cell lung cancer A meta-analysis . Cancer. 77:1996;2413-2414.
17. Gordon G.S., Vokes E.E. Chemoradiation for locally advanced, unresectable NSCLC. New standard of care, emerging strategies. Oncology (Huntingt). 13:1999;1075-1088.
18. Murphy W.K., Fossella F.V., Winn R.J., et al. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 85:1993;384-388.
19. Choy H., Browne M.J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Semin Oncol. 22:(3 Suppl. 6):1995;70-74.
20. Choy H., Safran H., Akerley W., et al. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res. 4:1998;1931-1936.
21. Belani C.P. Combined modality therapy for unresectable stage III non-small cell lung cancer New chemotherapy combinations . Chest. 117:(4 Suppl. 1):2000;127S-132S.
22. Lau D., Leigh B., Gandara D., et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer A California Cancer Consortium phase II trial . J Clin Oncol. 19:2001;442-447.
23. Ratanatharathorn V., Lorvidhaya V., Maoleekoonpairoj S., et al. Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer. 31:2001;257-265.
24. Choy H., Devore R.F. III, Hande K.R., et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys. 47:2000;931-937.
25. Dörr W., Baumann M., Herrmann T. Radiation-induced lung damage A challenge for radiation biology, experimental and clinical radiotherapy . Int J Radiat Biol. 76:2000;443-446.
26. Lee J.S., Scott C., Komaki R., et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer Radiation Therapy Oncology Group protocol 91-06 . J Clin Oncol. 14:1996;1055-1064.
27. Frasci G., Comella P., Scoppa G., et al. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer A phase I study . J Clin Oncol. 15:1997;1409-1417.
28. Castiglione F., Porcile G., Gridelli C. The potential role of amifostine in the treatment of non small cell lung cancer. Lung Cancer. 29:2000;57-66.
29. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Biol. 51:2001;915-922.
30. Capizzi R.L., Oster W. Chemoprotective and radioprotective effects of amifostine An update of clinical trials . Int J Hematol. 72:2000;425-435.
31. Practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol. 15:1997;2996-3018.
32. Roach M., Gandara D.R., You H.S., et al. Radiation pneumonitis following combined modality therapy for lung cancer Analysis of prognostic factors . J Clin Oncol. 13:1995;2606-2612.
33. Choy H., LaPorte K., Knill-Selby E., et al. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol. 9:(2 Suppl. 1):1999;90-96.
34. Choy H., Akerley W., Safran H., et al. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol. 12:1994;2682-2686.
35. Betticher D.C., Anderson H., Ranson M., et al. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer A randomised phase II study . Br J Cancer. 72:1995;1551-1555.
36. Tannehill S.P., Mehta M.P., Larson M., et al. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer Results of a phase II trial . J Clin Oncol. 15:1997;2850-2857.
37. Komaki R., Lee J.S., Kaplan B., et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer Preliminary results . Semin Radiat Oncol. 12:(Suppl. 1):2002;46-49.